FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology and radiation therapy, and can be used for photodynamic therapy with real-time control of efficacy. For that the delivery of the photosensitizer to the tumor cells is performed. Tetrapyrrole dye tetra(aryl)tetracyanoporphyrazine of the general formula is used as a photosensitizer:
,
where R is the expander, R=2-MeOPh (2-methoxyphenyl), or 4-MeOPh (4-methoxyphenyl), or 4-EtO-3-MeOPh (3-methoxy-4-phenetyl), or 3-C2H3Ph (3-vinylphenyl), or Phen (9-phenanthryl), or Et2NPh (4-diethylaminophenyl), or 4-C3H3OPh (4-(2-propynyloxy)phenyl), or 4-C3H3O-3-MeOPh (3-methoxy-4-(2-propynyloxy)phenyl), or 4-C3H3O-3-EtOPh (4-(2-propynyloxy)-3-phenetyl), or 4-BnO-3-MeOPh (3-methoxy-4-benzyloxyphenyl), or 4-BnO-EtOPh (4-benzyloxy-3-phenetyl), or 4-FBnO-3-MeOPh (3-methoxy-4-fluorobenzyloxyphenyl), or 4-FBnO-3-EtOPh (4-fluorobenzyloxy-3-ethoxyphenyl), or 4-BnOPh (4-benzyloxyphenyl), or 4-BrBnO-3-MeOPh (4-(benzyloxy)-3-methoxyphenyl), or 4-FPh (4-fluorophenyl), or 4-FBnOPh (4-fluorobenzyloxyphenyl), or 4-BrBnOPh (4-bromobenzyloxyphenyl). Next, fluorescence visualization of the tumor is performed and the lifetime of the excited state of the photosensitizer is determined when the maximum accumulation in the tumor is reached. Photodynamic destruction of the identified pathological focus is performed by fractionated stepwise irradiation with a central wavelength coinciding with the absorption spectrum of the photosensitizer. In this case, in the intervals between the stages of irradiation, the lifetime of the excited state of the photosensitizer is estimated. Procedure of photodynamic irradiation is repeated until the lifetime of the excited state of the photosensitizer is increased by 1.5–2 times relative to the initial level.
EFFECT: method provides an increase in the probability of the pathological formation complete removal in one session of photodynamic therapy while minimizing the negative impact on healthy tissues due to the individualization of the mode of photodynamic therapy using photosensitizers with the properties of viscous sensors.
6 cl, 2 tbl, 2 ex, 13 dwg
Title | Year | Author | Number |
---|---|---|---|
CYANOPORPHYRIN FREE BASE AND ITS USE | 2017 |
|
RU2665471C1 |
PORPHYRAZINE, GADOLINIUS PORPHYRAZINE COMPLEX AND THEIR APPLICATION | 2016 |
|
RU2621710C1 |
METHOD FOR ASSESSING THE CONTENT OF HYDROGEN PEROXIDE IN TUMOR CELLS IN PHOTODYNAMIC EXPOSURE | 2018 |
|
RU2700421C1 |
TETRA(BENZOTHIOPHEN-2-YL)TETRACYANOPORPHYRAZINE AS MULTIMODAL PHOTODYNAMIC THERAPY AGENT | 2018 |
|
RU2684623C1 |
TETRA(PYREN-1-YL)TETRACYANOPORPHYRAZINE AS A MULTIFUNCTIONAL AGENT FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2725641C1 |
METHOD FOR DETERMINING OPTIMAL ENERGY PARAMETERS OF LASER-INDUCED PHOTODYNAMIC THERAPY OF DYSPLASIA AND CERVICAL CANCER | 2023 |
|
RU2815258C1 |
PHOTOSENSITISER FOR PHOTODYNAMIC THERAPY | 2013 |
|
RU2549953C2 |
METHOD OF PHOTODYNAMIC THERAPY | 2014 |
|
RU2552032C1 |
METHOD OF PHOTODYNAMIC THERAPY OF TUMOURS | 2012 |
|
RU2519936C2 |
DEVICE FOR FLUORESCENT DIAGNOSIS AND MONITORING OF PHOTODYNAMIC THERAPY | 2015 |
|
RU2596869C1 |
Authors
Dates
2018-11-19—Published
2017-12-07—Filed